Holen Sie sich die Stockscreener-App
313.40
5.30%
-17.54
Handel nachbörslich:
313.40
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt MDGL?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$330.94
Offen:
$329.5
24-Stunden-Volumen:
583.50K
Relative Volume:
1.70
Marktkapitalisierung:
$6.96B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-518.67M
KGV:
-12.48
EPS:
-25.12
Netto-Cashflow:
$-438.32M
1W Leistung:
+0.73%
1M Leistung:
+9.68%
6M Leistung:
-3.48%
1J Leistung:
+9.17%
1-Tages-Spanne:
$312.50
$332.75
1-Wochen-Bereich:
$312.50
$357.91
52-Wochen-Spanne:
$200.63
$377.46
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Firmenname
Madrigal Pharmaceuticals Inc
Sektor
Branche
Telefon
404-380-9263
Adresse
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Vergleichen Sie MDGL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
313.40 | 6.91B | 0 | -518.67M | -438.32M | -25.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-28 | Hochstufung | B. Riley Securities | Neutral → Buy |
| 2025-02-27 | Bestätigt | H.C. Wainwright | Buy |
| 2024-06-28 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-06-11 | Eingeleitet | Wolfe Research | Outperform |
| 2024-04-22 | Eingeleitet | BofA Securities | Underperform |
| 2024-03-15 | Hochstufung | B. Riley Securities | Sell → Neutral |
| 2024-03-06 | Eingeleitet | Citigroup | Buy |
| 2024-02-26 | Herabstufung | B. Riley Securities | Neutral → Sell |
| 2022-12-20 | Bestätigt | Oppenheimer | Outperform |
| 2022-12-19 | Bestätigt | H.C. Wainwright | Buy |
| 2022-12-19 | Bestätigt | Piper Sandler | Overweight |
| 2022-12-19 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2022-07-08 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-08-06 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-05-20 | Fortgesetzt | Goldman | Buy |
| 2020-11-24 | Fortgesetzt | Evercore ISI | Outperform |
| 2020-11-06 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-31 | Eingeleitet | Piper Sandler | Overweight |
| 2020-06-05 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2020-05-05 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-01-30 | Eingeleitet | Canaccord Genuity | Buy |
| 2020-01-09 | Hochstufung | UBS | Neutral → Buy |
| 2019-11-07 | Bestätigt | H.C. Wainwright | Buy |
| 2019-06-25 | Eingeleitet | Stifel | Hold |
| 2019-06-10 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2019-02-28 | Bestätigt | H.C. Wainwright | Buy |
| 2019-02-22 | Eingeleitet | SVB Leerink | Outperform |
| 2019-01-23 | Eingeleitet | UBS | Neutral |
| 2018-12-14 | Eingeleitet | Wolfe Research | Outperform |
| 2018-12-12 | Eingeleitet | B. Riley FBR | Neutral |
| 2018-11-19 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2018-11-16 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-09-04 | Eingeleitet | Citigroup | Buy |
| 2018-08-06 | Herabstufung | Goldman | Buy → Neutral |
| 2018-06-28 | Eingeleitet | Raymond James | Mkt Perform |
Alle ansehen
Madrigal Pharmaceuticals Inc Aktie (MDGL) Neueste Nachrichten
What analysts say about Madrigal Pharmaceuticals Inc. stockSuperior portfolio returns - jammulinksnews.com
Is Madrigal Pharmaceuticals Inc. a good long term investmentHigh-profit trading signals - jammulinksnews.com
Madrigal Pharmaceuticals Secures $500 Million in Senior - GlobeNewswire
Madrigal's $500M Financing: Cementing Leadership in the High-Growth MASH Market - AInvest
Madrigal Pharmaceuticals Secures $500M Credit Facility - TipRanks
Madrigal Pharmaceuticals (MDGL) Secures $500 Million Credit Facility - GuruFocus
Madrigal Pharmaceuticals Secures $500 Million in Senior Secured - GuruFocus
Madrigal secures $500 million credit facility to advance MASH pipeline By Investing.com - Investing.com Nigeria
Madrigal Pharmaceuticals Secures $500 Million Senior Secured Credit Facility to Enhance MASH Pipeline and Support Strategic Expansion - Quiver Quantitative
Citizens JMP reiterates Madrigal stock rating on strong Rezdiffra uptake By Investing.com - Investing.com Canada
What drives Madrigal Pharmaceuticals Inc. stock priceOutstanding growth strategies - jammulinksnews.com
10 Most Undervalued Healthcare Stocks To Buy According To Analysts - Insider Monkey
Madrigal Pharmaceuticals Inc. Stock Analysis and ForecastConsistently outstanding ROI - Autocar Professional
Madrigal Pharmaceuticals shares surge after extended patent protection for MASH therapy - MSN
Madrigal Pharmaceuticals Secures Key Patent for Rezdiffra, Extending Market Protection to 2044 - MSN
Madrigal gains after Rezdiffra patent win - MSN
MDGL Stock Soars 11% on New Patent Protecting Rezdiffra Dosing Rights - MSN
Madrigal Pharmaceuticals Grants Equity Awards to 30 New Team Members - MSN
Madrigal (MDGL) Moves 10.9% Higher: Will This Strength Last? - Yahoo Finance
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
When (MDGL) Moves Investors should Listen - news.stocktradersdaily.com
Madrigal Pharmaceuticals receives notice of allowance for Rezdiffra patent - TipRanks
Madrigal Pharmaceuticals Surges to 222nd in Daily Rankings with $451 Million Turnover - AInvest
Madrigal Pharmaceuticals: Strong Surge or Overpriced? - StocksToTrade
Madrigal Pharmaceuticals stock price target raised by Oppenheimer on patent news - Investing.com Canada
Madrigal’s Surge: Breakthrough in Liver Treatment? - timothysykes.com
Madrigal Pharmaceuticals Soars: Is It Time to Buy? - StocksToTrade
Madrigal Pharmaceuticals (MDGL) Surges Over 12% in Market Gains - GuruFocus
Madrigal Pharmaceuticals (MDGL) Soars on Rezdiffra Patent Approval - GuruFocus
Madrigal gains after Rezdiffra patent win (MDGL:NASDAQ) - Seeking Alpha
Madrigal stock jumps as patent protection for MASH treatment extended By Investing.com - Investing.com Nigeria
Madrigal stock jumps as patent protection for MASH treatment extended - Investing.com
Madrigal receives patent allowance for MASH treatment Rezdiffra By Investing.com - Investing.com India
Why Madrigal Pharmaceuticals Inc. stock attracts strong analyst attentionFree Stock Investment Growth Plan - beatles.ru
Madrigal Pharmaceuticals (MDGL) Secures Patent for Rezdiffra Use - GuruFocus
Madrigal Pharmaceuticals Announces FDA Patent Allowance for Rezdiffra™ Providing Protection Through September 2044 - Quiver Quantitative
Madrigal Pharmaceuticals Receives Notice of Allowance from - GlobeNewswire
Madrigal Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for New U.S. Patent Covering Rezdiffra™ (Resmetirom) - Yahoo Finance
Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) Shift From Loss To Profit - 富途牛牛
Loss-Making Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Expected To Breakeven In The Medium-Term - simplywall.st
MDGL Makes Notable Cross Below Critical Moving Average - Nasdaq
Madrigal Pharmaceuticals’ SWOT analysis: rezdiffra’s strong launch propels stock outlook - Investing.com
JMP Reaffirms Price Target for Madrigal Amid Rezdiffra Growth Potential - Yahoo Finance
Madrigal Pharmaceuticals (MDGL) Sees Stock Surge After Competito - GuruFocus
Altimmune’s phase IIb in MASH hits and misses, stock halves - BioWorld MedTech
Madrigal Pharmaceuticals Closer to EU Approval for First MASH Treatment, Rezdiffra - Yahoo Finance
Madrigal Pharmaceuticals: GLP-1s Inch Closer To MASH Market As REZDIFFRA Outperform (MDGL) - Seeking Alpha
Madrigal Pharmaceuticals Receives Positive CHMP Opinion for Resmetirom in Treating MASH - MyChesCo
Finanzdaten der Madrigal Pharmaceuticals Inc-Aktie (MDGL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):